Novamycin (NP339)

Novamycin® (NP339) is a novel antifungal peptide developed for front-line treatment of medically unmet, yeast and mould infections, particularly those caused by Aspergillus spp. and Candida spp.

Mortality rates for Aspergillus infections are as high as 80% (100% without treatment) and Candida remains the most common cause (over 50%) of hospital based (nosocomial) blood stream or deep tissue fungal infections. Invasive fungal disease (IFD), caused by these and other fungal pathogens, is a growing medical problem associated with a failure or inability of the body’s immune system to fight off opportunistic fungi.

Clinical and Commercial Development

Novamycin is unique as the first antifungal in development for the treatment of fungal disease as an inhaled, systemic and mucocutaneous therapy. NP339 is a rapidly acting fungicidal peptide that has demonstrated superiority over existing antifungal classes in preclinical testing (with a placebo like safety profile) for a number of fungal infections. Novamycin is expected to undergo initial PhI safety clinical testing (systemic delivery), initial clinical studies in 2018 for respiratory aspergillosis (Aspergillus infection in the lung which can become disseminated throughout the body) and oral pharyngeal candidiasis (Candida infection of the mouth and pharynx; often referred to as thrush). Novamycin is derived from the same peptide technology platform as Novexatin/NP213 and so the route to clinic and market for Novamycin has already been significantly de-risked.

Molecule Class

Novamycin is a novel, potent synthetic antimicrobial peptide (AMP) generated from NovaBiotics rational drug design technology platform. Specifically, Novamycin is a poly-Arginine based cationic peptide.

Mechanism of Action

Novamycin acts through membrane perturbation and lysis; this mode of action rapidly killing both non-metabolising and metabolically active fungi. This mechanism of action minimises or negates the risk of acquired drug resistance. Novamycin has been shown to be active against pathogens that are resistant/insensitive to conventional antifungals and has a placebo-like safety profile.

Date of article/Start date of trial: 5 October 2017

Our sponsors